phrykt

Atossa Therapeutics, Inc. (ATOS): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of ATOS were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No ATOS insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ATOS short interest

Moderate short interest. 5.3% of ATOS shares are sold short: about 1 share in 19. Over the last 12 reports the number of shares short went up 54%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 526,812 ATOS shares were sold short, 5.3% of the shares outstanding, down 22.9% from the report before. At the average daily volume of 69,379 shares, buying them all back would take about 7.6 trading days (days to cover).

Shares short, % of all shares

5.28%May 15Oct 309.77%

Days to cover

7.6May 15Oct 3018.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026526,8125.28%-23%69,3797.6
Oct 15, 2026683,5396.85%-13%116,8525.8
Sep 30, 2026788,3347.90%+3%69,72011.3
Sep 15, 2026762,1567.64%+1%47,07316.2
Aug 31, 2026755,7767.57%-5%60,46012.5
Aug 14, 2026795,4577.97%+5%55,38614.4
Jul 31, 2026760,1277.62%-2%56,38013.5
Jul 15, 2026776,2469.01%+10%166,4414.7
Jun 30, 2026704,0178.18%+32%320,2932.2
Jun 15, 2026533,3436.19%+33%262,4362.0
May 29, 2026400,9964.66%+17%41,9099.6
May 15, 2026341,3443.96%+1%61,0475.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Atossa Therapeutics company events

Atossa Therapeutics filed 15 reports on Form 8-K in the last 12 months, 1 of them about an important change (listing). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Oct 9, 2026AgreementThe Board of Directors of Atossa Therapeutics, Inc. declared a dividend of one stapled contingent value right (a “Stapled CVR”) for each share of the Company’s common stock, par value $0.18 per share, outstanding at the close of business on October 19, 2026, and authorized the issuance of one… Filing
  3. Sep 29, 2026AnnouncementAtossa Therapeutics, Inc. announced that its board of directors has approved a plan to issue one contingent value right to each share of the Company’s common stock to enable stockholders to share in a portion of any proceeds received from the monetization of the Company’s first qualifying rare… Filing
  4. Sep 18, 2026AnnouncementShared information with investors. Filing
  5. Aug 7, 2026ResultsReleased financial results. Filing
  6. Jun 11, 2026AgreementAtossa Therapeutics, Inc. entered into a securities purchase agreement with institutional investors, providing for the issuance and sale by the Company, in a registered direct offering, of (i) 1,363,638 shares of the Company’s common stock, par value $0.18 and (ii) Series A warrants to purchase up… Filing
  7. May 8, 2026VoteReported shareholder vote results. Filing
  8. Apr 16, 2026AnnouncementAtossa Therapeutics, Inc. announced that on April 13, 2026, the Company entered into a Settlement Agreement with Intas Pharmaceuticals Ltd. and Jina Pharmaceuticals, Inc., which is intended to resolve patent disputes related to Endoxifen-related intellectual property, including pending proceedings… Filing
  9. Feb 20, 2026AgreementAtossa Therapeutics, Inc. entered into the At the Market Offering Agreement, dated February 20, 2026, with Rodman & Renshaw LLC, pursuant to which the Company may offer and sell from time to time up to $50 million of shares of the Company’s common stock, par value $0.18 per share, through the Sales… Filing
  10. Feb 17, 2026ListingAtossa Therapeutics, Inc. received a letter from The Nasdaq Stock Market LLC informing the Company that it had regained compliance with the minimum closing bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Filing
  11. Feb 11, 2026AnnouncementShared information with investors. Filing
  12. Jan 26, 2026SharesChanged the rights of its shareholders. Filing
  13. Jan 9, 2026ResultsReleased financial results. Filing
  14. Jan 6, 2026AnnouncementAtossa Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration issued a "Study May Proceed" letter for the Company's study of metastatic breast cancer. Filing
  15. Dec 4, 2025AnnouncementAtossa Therapeutics, Inc. issued a press release announcing the completion of a Type C meeting with the U.S. Food and Drug Administration on November 17, 2025 to review regulatory strategy for advancing (Z)-endoxifen. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Atossa Therapeutics financials

Famous investors that hold ATOS

2 of the 50 well-known investors we track reported holding ATOS in their latest 13F filing. The largest position is Jim Simons's, worth $214K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026109,907$214K0.0%-17%
Israel Englander · Millennium ManagementQ3 202614,867$29K0.0%-68%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Atossa Therapeutics, Inc. (ATOS) stock

Are ATOS insiders buying or selling?

No ATOS insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in ATOS?

As of Oct 30, 2026, 526,812 ATOS shares were sold short, 5.3% of the shares outstanding, down 22.9% from the report before. At the average daily volume of 69,379 shares, buying them all back would take about 7.6 trading days (days to cover). See the history.

Which famous investors hold ATOS?

2 of the 50 well-known investors we track reported ATOS in their latest 13F filing, including Jim Simons, Israel Englander. The largest position is worth $214K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.